Literature DB >> 23812558

Cardioprotective functions of HDLs.

Kerry-Anne Rye1, Philip J Barter.   

Abstract

Multiple human population studies have established the concentration of high density lipoprotein (HDL) cholesterol as an independent, inverse predictor of the risk of having a cardiovascular event. Furthermore, HDLs have several well-documented functions with the potential to protect against cardiovascular disease. These include an ability to promote the efflux of cholesterol from macrophages in the artery wall, inhibit the oxidative modification of low density lipoproteins (LDLs), inhibit vascular inflammation, inhibit thrombosis, promote endothelial repair, promote angiogenesis, enhance endothelial function, improve diabetic control, and inhibit hematopoietic stem cell proliferation. There are undoubtedly other beneficial functions of HDLs yet to be identified. The HDL fraction in human plasma is heterogeneous, consisting of several subpopulations of particles of varying size, density, and composition. The functions of the different HDL subpopulations remain largely unknown. Given that therapies that increase the concentration of HDL cholesterol have varying effects on the levels of specific HDL subpopulations, it is of great importance to understand how distribution of different HDL subpopulations contribute to the potentially cardioprotective functions of this lipoprotein fraction. This review summarizes current understanding of the relationship of HDL subpopulations to their cardioprotective properties and highlights the gaps in current knowledge regarding this important aspect of HDL biology.

Entities:  

Keywords:  angiogenesis; apoptosis; cholesterol efflux; endothelial function; endothelial repair; oxidation; pancreatic beta cell function; thrombosis; vascular inflammation

Mesh:

Substances:

Year:  2013        PMID: 23812558      PMCID: PMC3886656          DOI: 10.1194/jlr.R039297

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  126 in total

1.  High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase.

Authors:  I S Yuhanna; Y Zhu; B E Cox; L D Hahner; S Osborne-Lawrence; P Lu; Y L Marcel; R G Anderson; M E Mendelsohn; H H Hobbs; P W Shaul
Journal:  Nat Med       Date:  2001-07       Impact factor: 53.440

2.  Time sequence of the inhibition of endothelial adhesion molecule expression by reconstituted high density lipoproteins.

Authors:  M A Clay; D H Pyle; K A Rye; M A Vadas; J R Gamble; P J Barter
Journal:  Atherosclerosis       Date:  2001-07       Impact factor: 5.162

3.  A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits.

Authors:  H Okamoto; F Yonemori; K Wakitani; T Minowa; K Maeda; H Shinkai
Journal:  Nature       Date:  2000-07-13       Impact factor: 49.962

Review 4.  Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I.

Authors:  Kerry-Anne Rye; Philip J Barter
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-10-30       Impact factor: 8.311

5.  Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.

Authors:  Margaret E Brousseau; Ernst J Schaefer; Megan L Wolfe; LeAnne T Bloedon; Andres G Digenio; Ronald W Clark; James P Mancuso; Daniel J Rader
Journal:  N Engl J Med       Date:  2004-04-08       Impact factor: 91.245

6.  High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors.

Authors:  Takao Kimura; Koichi Sato; Enkhzol Malchinkhuu; Hideaki Tomura; Kenichi Tamama; Atsushi Kuwabara; Masami Murakami; Fumikazu Okajima
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-05-29       Impact factor: 8.311

7.  Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein.

Authors:  Radjesh J Bisoendial; G Kees Hovingh; Johannes H M Levels; Peter G Lerch; Irmgard Andresen; Michael R Hayden; John J P Kastelein; Erik S G Stroes
Journal:  Circulation       Date:  2003-05-27       Impact factor: 29.690

8.  Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial.

Authors:  Steven E Nissen; Taro Tsunoda; E Murat Tuzcu; Paul Schoenhagen; Christopher J Cooper; Muhammad Yasin; Gregory M Eaton; Michael A Lauer; W Scott Sheldon; Cindy L Grines; Stephen Halpern; Tim Crowe; James C Blankenship; Richard Kerensky
Journal:  JAMA       Date:  2003-11-05       Impact factor: 56.272

9.  Reconstituted high-density lipoprotein exhibits neuroprotection in two rat models of stroke.

Authors:  Roberto Paternò; Antonio Ruocco; Alfredo Postiglione; Alphonse Hubsch; Irmgard Andresen; Markus G Lang
Journal:  Cerebrovasc Dis       Date:  2003-12-29       Impact factor: 2.762

10.  Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content.

Authors:  Ann M Poynten; Seng Khee Gan; Adamandia D Kriketos; Anthony O'Sullivan; John J Kelly; Bronwyn A Ellis; Donald J Chisholm; Lesley V Campbell
Journal:  Metabolism       Date:  2003-06       Impact factor: 8.694

View more
  100 in total

1.  HDL inhibits the effects of oxidized phospholipids on endothelial cell gene expression via multiple mechanisms.

Authors:  Benjamin Emert; Yehudit Hasin-Brumshtein; James R Springstead; Ladan Vakili; Judith A Berliner; Aldons J Lusis
Journal:  J Lipid Res       Date:  2014-05-23       Impact factor: 5.922

Review 2.  Exploring the dark genome: implications for precision medicine.

Authors:  Tudor I Oprea
Journal:  Mamm Genome       Date:  2019-07-04       Impact factor: 2.957

3.  Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA.

Authors:  Ruud S Kootte; Loek P Smits; Fleur M van der Valk; Jean-Louis Dasseux; Constance H Keyserling; Ronald Barbaras; John F Paolini; Raul D Santos; Theo H van Dijk; Geesje M Dallinga-van Thie; Aart J Nederveen; Willem J M Mulder; G Kees Hovingh; John J P Kastelein; Albert K Groen; Erik S Stroes
Journal:  J Lipid Res       Date:  2015-01-05       Impact factor: 5.922

4.  Biomarkers of response to alpha-lipoic acid ± palmitoiletanolamide treatment in patients with diabetes and symptoms of peripheral neuropathy.

Authors:  Silvia Pieralice; Riccardo Vari; Alessandra Minutolo; Anna Rita Maurizi; Elvira Fioriti; Nicola Napoli; Paolo Pozzilli; Silvia Manfrini; Ernesto Maddaloni
Journal:  Endocrine       Date:  2019-04-04       Impact factor: 3.633

Review 5.  Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.

Authors:  Shipra Agrawal; Joshua J Zaritsky; Alessia Fornoni; William E Smoyer
Journal:  Nat Rev Nephrol       Date:  2017-11-27       Impact factor: 28.314

6.  Restoration of renal function does not correct impairment of uremic HDL properties.

Authors:  Chantal Kopecky; Michael Haidinger; Ruth Birner-Grünberger; Barbara Darnhofer; Christopher C Kaltenecker; Gunther Marsche; Michael Holzer; Thomas Weichhart; Marlies Antlanger; Johannes J Kovarik; Johannes Werzowa; Manfred Hecking; Marcus D Säemann
Journal:  J Am Soc Nephrol       Date:  2014-07-28       Impact factor: 10.121

7.  HDL in CKD: how good is the "good cholesterol?".

Authors:  Ian H de Boer; John D Brunzell
Journal:  J Am Soc Nephrol       Date:  2014-03-07       Impact factor: 10.121

Review 8.  High-density lipoprotein mimetics: promises and challenges.

Authors:  Dmitri Sviridov; Alan T Remaley
Journal:  Biochem J       Date:  2015-12-15       Impact factor: 3.857

Review 9.  Quantifying HDL proteins by mass spectrometry: how many proteins are there and what are their functions?

Authors:  Baohai Shao; Jay W Heinecke
Journal:  Expert Rev Proteomics       Date:  2017-11-13       Impact factor: 3.940

Review 10.  From High-Density Lipoprotein Cholesterol to Measurements of Function: Prospects for the Development of Tests for High-Density Lipoprotein Functionality in Cardiovascular Disease.

Authors:  Frank M Sacks; Majken K Jensen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-01-25       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.